Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Cisplatin Induction, Concurrent Cisplatin Chemoradiotherapy, and Docetaxel plus Cisplatin Adjuvant in High-risk Nasopharyngeal Carcinoma
ChiCTR-OIC-16008204Phase 2Recruiting
- Sponsor
- Huizhou Central People's Hospital
- Start
- Apr 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Huizhou Central People's Hospital. Primary endpoint: distant failure-free survival rate. Started Apr 2016; status: recruiting.
02
Drugs
docetaxelcisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-OIC-16008204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008204.